靶向ALK:精准医学应对耐药
本文综述了靶向间变性淋巴瘤激酶(ALK)在ALK重排恶性肿瘤(包括非小细胞肺癌)中的成功与挑战,重点阐述ALK酪氨酸激酶抑制剂(TKI)耐药机制的多样性,并讨论基于机制克服耐药的策略。文章强调连续活检对捕捉肿瘤动态治疗脆弱性的重要性,指出能成功克服并可能预防耐药的治疗策略将对患者结局产生最大影响。
要点
- ALK是多种ALK重排恶性肿瘤(包括非小细胞肺癌)的验证性分子靶点。
- ALK TKI的临床获益几乎普遍受限于耐药性的出现。
- 已发现多种ALK TKI耐药机制,为开发克服耐药的策略提供依据。
核心结论
- 有效长期治疗ALK重排癌症需要从机制上理解ALK TKI耐药,以便选择合理疗法对抗耐药。
- 能成功克服并可能预防耐药机制的治疗策略将对患者结局产生最大影响。
研究设计与样本
- 本文为综述,总结当前靶向ALK的成功与挑战,并讨论已发现的ALK TKI耐药机制及克服耐药的策略。
主要发现
- ALK TKI的临床获益几乎普遍受限于耐药性的出现。
- 已发现多种ALK TKI耐药机制,这些基本机制为开发新型治疗策略以在临床中克服耐药提供了信息。
- 连续活检有助于捕捉患者肿瘤内的动态治疗脆弱性。
- ALK TKI耐药机制包括靶内和靶外机制,具有复杂性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, including non-small cell lung cancer. However, the clinical benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance. Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. In this review, we summarize the current successes and challenges of targeting ALK. SIGNIFICANCE: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance. This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms. Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome. Cancer Discov; 7(2); 137-55. ©2017 AACR.
引用
- Lin JJ, Riely GJ, Shaw AT, et al. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov. 2017. PMID: 28122866. doi:10.1158/2159-8290.CD-16-1123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。